Helen Mann

11.2k total citations · 4 hit papers
94 papers, 6.1k citations indexed

About

Helen Mann is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Helen Mann has authored 94 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Oncology, 55 papers in Pulmonary and Respiratory Medicine and 11 papers in Surgery. Recurrent topics in Helen Mann's work include Lung Cancer Treatments and Mutations (45 papers), Cancer Immunotherapy and Biomarkers (22 papers) and Colorectal Cancer Treatments and Studies (21 papers). Helen Mann is often cited by papers focused on Lung Cancer Treatments and Mutations (45 papers), Cancer Immunotherapy and Biomarkers (22 papers) and Colorectal Cancer Treatments and Studies (21 papers). Helen Mann collaborates with scholars based in United Kingdom, United States and Japan. Helen Mann's co-authors include Suresh S. Ramalingam, Serban Ghiorghiu, Yi‐Long Wu, Frances A. Shepherd, Myung‐Ju Ahn, Tony Mok, Chee Khoon Lee, Willemijn S.M.E. Theelen, Marcelo Marotti and Vassiliki A. Papadimitrakopoulou and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Helen Mann

90 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

2016 2.4k citations Tony Mok, Yi‐Long Wu et al. profile →
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

2016 502 citations Helen Mann, Serban Ghiorghiu et al. profile →
Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer

2017 380 citations James Chih‐Hsin Yang, Chee Khoon Lee et al. profile →
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

2020 303 citations Helen Mann, Dana Ghiorghiu et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Helen Mann United Kingdom	31	4.6k	4.1k	1.6k	1.2k	370	94	6.1k
Chee Khoon Lee Australia	33	4.9k 1.1×	5.2k 1.3×	1.8k 1.1×	1.6k 1.3×	522 1.4×	178	7.4k
Janusz Rolski Poland	15	2.8k 0.6×	2.8k 0.7×	763 0.5×	800 0.7×	359 1.0×	45	4.2k
Johannes Ettl Germany	29	3.2k 0.7×	4.2k 1.0×	1.3k 0.8×	1.6k 1.3×	125 0.3×	132	5.5k
Tomasz Demkow Poland	21	4.3k 0.9×	2.2k 0.5×	3.6k 2.2×	2.3k 1.9×	773 2.1×	77	6.6k
Vincenzo Adamo Italy	27	2.2k 0.5×	2.4k 0.6×	1.0k 0.6×	699 0.6×	367 1.0×	118	3.8k
M. Pérol France	33	5.4k 1.2×	4.7k 1.1×	1.5k 0.9×	1.3k 1.0×	395 1.1×	292	7.0k
Rashmi Chugh United States	39	2.5k 0.6×	2.1k 0.5×	1.5k 0.9×	547 0.4×	432 1.2×	172	4.9k
Orazio Caffo Italy	36	2.0k 0.4×	2.4k 0.6×	1.4k 0.8×	1.4k 1.1×	764 2.1×	230	4.8k
Dimosthenis Skarlos Greece	31	2.1k 0.5×	4.9k 1.2×	1.5k 0.9×	873 0.7×	545 1.5×	104	6.4k
Wenting Wu China	9	1.8k 0.4×	2.7k 0.7×	1.5k 0.9×	1.0k 0.8×	119 0.3×	23	4.0k

Countries citing papers authored by Helen Mann

Since Specialization

Citations

This map shows the geographic impact of Helen Mann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen Mann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen Mann more than expected).

Fields of papers citing papers by Helen Mann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen Mann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen Mann. The network helps show where Helen Mann may publish in the future.

Co-authorship network of co-authors of Helen Mann

This figure shows the co-authorship network connecting the top 25 collaborators of Helen Mann. A scholar is included among the top collaborators of Helen Mann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helen Mann. Helen Mann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Navarro, A. Bañón, et al.. (2026). Patient-Reported Outcomes with Consolidation Durvalumab Versus Placebo Following Concurrent Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer: Results from the Phase 3 ADRIATIC Trial. Journal of Thoracic Oncology. 103564–103564.

Cheng, Ying, David R. Spigel, Jian Fang, et al.. (2024). MA17.04 Patient-Reported Outcomes (PROs) With Consolidation Durvalumab Versus Placebo Following cCRT in Limited-Stage SCLC: ADRIATIC. Journal of Thoracic Oncology. 19(10). S124–S125. 1 indexed citations

Barlési, Fabrice, Byoung Chul Cho, Sarah B. Goldberg, et al.. (2024). PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer. Future Oncology. 20(29). 2137–2147. 17 indexed citations

Heymach, John V., David H. Harpole, Tetsuya Mitsudomi, et al.. (2023). Abstract CT005: AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC. Cancer Research. 83(8_Supplement). CT005–CT005. 55 indexed citations

Cheng, Ying, Qing Zhou, Baohui Han, et al.. (2023). NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer. Lung Cancer. 178. 87–95. 6 indexed citations

Garon, Edward B., Byoung Chul Cho, Alexander Luft, et al.. (2023). Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON). Lung Cancer. 186. 107422–107422. 4 indexed citations

Ahn, Myung‐Ju, Igor Bondarenko, Ewa Kalinka‐Warzocha, et al.. (2023). Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study. Journal of Thoracic Oncology. 18(11). 1594–1606. 8 indexed citations

He, Zhijian, Vincent Duval, António Gonçalves, et al.. (2023). Population Pharmacokinetics and Exposure–Response Analysis for the CTLA‐4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON Study. Clinical Pharmacology & Therapeutics. 114(6). 1375–1386. 2 indexed citations

Oh, D-Y., Yelena Y. Janjigian, S-E. Al-Batran, et al.. (2023). 129O Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study. Annals of Oncology. 34. S1520–S1521. 5 indexed citations

10.

Garon, Edward B., Byoung Chul Cho, Alexander Luft, et al.. (2022). 5MO Patient reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON. Annals of Oncology. 33. S29–S30. 2 indexed citations

11.

Ouwens, Mario, Annie Darilay, P. Mukhopadhyay, et al.. (2019). Impact of subsequent post-discontinuation immunotherapy on overall survival in patients with unresectable, stage III NSCLC from PACIFIC. Annals of Oncology. 30. ii31–ii31. 1 indexed citations

12.

Knox, Jennifer J., Ann‐Lii Cheng, Sean P. Cleary, et al.. (2019). A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence after curative hepatic resection. Annals of Oncology. 30. iv51–iv51. 6 indexed citations

13.

Davis, Rachel, et al.. (2017). Effectiveness of a Multidisciplinary Rehabilitation Program Following Shoulder Injury. SHILAP Revista de lepidopterología. 5(3). 3 indexed citations

14.

Mok, Tony, Yi‐Long Wu, M. Ahn, et al.. (2017). Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. QUT ePrints (Queensland University of Technology). 290 indexed citations

15.

Cho, Byoung Chul, K.H. Lee, Arunee Dechaphunkul, et al.. (2017). Osimertinib vs standard of care (SoC) EGFR-TKI as first-line treatment in patients with EGFR-TKI sensitising mutation (EGFRm) positive advanced non-small cell lung cancer (NSCLC): FLAURA Asian subset. Annals of Oncology. 28. x190–x190. 2 indexed citations

16.

Lee, Chee Khoon, Silvia Novello, Anna Rydén, et al.. (2017). Patient-reported symptoms and impact of treatment with osimertinib vs chemotherapy for advanced non-small cell lung cancer. Annals of Oncology. 28. ii30–ii30. 1 indexed citations

17.

Ledermann, Jonathan A., Philipp Harter, Charlie Gourley, et al.. (2016). Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. UCL Discovery (University College London). 1 indexed citations

18.

Andersohn, Frank, Helen Mann, Tetsuya Mitsudomi, et al.. (2016). Adjusted indirect comparison using propensity score matching of osimertinib to doublet chemotherapy in patients with EGFRm T790M NSCLC who have progressed after EGFR-TKI. Annals of Oncology. 27. vi430–vi430. 1 indexed citations

19.

Zhao, Binsheng, Yongqiang Tan, Daniel J. Bell, et al.. (2013). Exploring intra- and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervals. European Journal of Radiology. 82(6). 959–968. 74 indexed citations

20.

Hanrahan, Emer O., Anderson J. Ryan, Helen Mann, et al.. (2009). Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer. Clinical Cancer Research. 15(10). 3600–3609. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact